Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial
OBJECTIVE: To evaluate open-label adalimumab therapy for clinical effectiveness, fistula healing, patient-reported outcomes and safety in Canadian patients with moderate to severe Crohn’s disease (CD) who were either naive to or previously exposed to antitumour necrosis factor (anti-TNF) therapy.
Saved in:
Main Authors: | Remo Panaccione, Edward V Loftus, David Binion, Kevin McHugh, Shamsul Alam, Naijun Chen, Benoît Guérette, Parvez Mulani, Jingdong Chao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2011/724813 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease
by: Yin-mei Fu, et al.
Published: (2017-01-01) -
Acute Pancreatitis: An Unusual Side Effect of Adalimumab in Crohn’s Disease Patient
by: Walid El Ouardi, et al.
Published: (2025-01-01) -
Establishment and internal validation of a model to predict the efficacy of Adalimumab in Crohn’s disease
by: Fang Wang, et al.
Published: (2025-01-01) -
Disutility Study for Adult Patients with Moderate to Severe Crohn’s Disease
by: Melany Worbes-Cerezo, et al.
Published: (2019-03-01) -
Adalimumab induced psoriasis in Crohn’s disease and treatment with ustekinumab: case report and special histopathological findings
by: Fang Qiu, et al.
Published: (2025-01-01)